top of page
BGV4.png

Extending Survival and
Improving Quality of Life

Introducing AOH1996

A potent, next-generation drug to meet the need​

  • aggressively fighting cancer

  • reducing toxic side effects

RLL has developed a First-in-Class oral drug with a unique Mechanism of Action that pre-clinical data establishes:

Blocks cancer cell growth, repair, and replication

Binds to the molecule that is a central driver of cancer cell proliferation 

Highly Selective

Little-to-no impact on normal cells and low-to-no toxicity, unlike most other cancer therapeutic drugs

Improved efficacy in combination with current Standard of Care chemotherapies

Enabling lower doses of the chemotherapies and reducing toxic side effects

Maintains Effectiveness

Cancer cells do not appear to develop resistance

Image 2_edited.jpg

Our Mission

Extending Survival and Improving Quality of Life

Group 1301.png
Minimal Toxicity

By specifically targeting cancer cells and sparing healthy cells, AOH1996 reduces the overall toxicity of treatment. In ongoing Phase 1 clinical trials, patients receiving AOH1996 have experienced little-to-no side effects attributable to AOH1996.

Enhanced Efficacy with Combination Therapy

In preclinical studies, AOH1996's synergistic effects have been shown to improve overall treatment outcomes with the potential to lower the dosage of other therapies, potentially reducing overall toxicity.

Reduced Development of Resistance

In preclinical studies, AOH1996 appears to limit the ability of cancer cells to develop resistance and inhibits at least 9 distinct biochemical pathways required for cancer cell progression and maintenance, potentially ensuring long-term effectiveness.

RLLNEWLOGO.png

Included herein is information regarding RLL, LLC which may include, among other information, financial and/or scientific projections and prospects. Please note that the projections are based upon assumptions, some of which may change substantially before a confidential memorandum or other offering materials are prepared, some or all of which may not materialize. The information provided does not constitute any offer to sell or any solicitation of any offer to purchase any security, which offer will be made, if at all, only by a confidential memorandum or other offering materials prepared for such use and including applicable risk factors for the Company's offering and information regarding the securities laws of the applicable jurisdictions in which offers and sales are intended to occur.

© 2025 by RLL, LLC.

bottom of page